This study develops and validates a prognostic model for patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus lenvatinib.

• Identified nine key risk factors impacting overall and progression-free survival, including tumor number and extrahepatic metastases.
• Survival prediction model showed area under the curve values of 0.706 at 3 years for overall survival and 0.702 for progression-free survival.

Surgeons can use this model to guide clinical decisions and optimize patient selection for this therapy.

• Triple therapy was a notable protective factor for survival outcomes.

Evaluating nutrition and body composition can enhance post-surgery success in pancreaticoduodenectomy.

• 57.2% of patients achieved a textbook outcome, with no 30-day mortality.
• Key risk factors for not achieving a textbook outcome include age ≥75, malnutrition, and a high visceral fat to muscle ratio.

Focusing on these factors preoperatively may significantly improve patient outcomes and overall survival rates.

• Patients meeting textbook outcomes experienced better overall survival compared to those who did not.

Early-stage pancreatic cancer outcomes hinge on lymph node counts, affecting surgical decisions.

• Optimal examined lymph nodes for best survival in stage I and II is ≥10.
• Stage II patients benefit most with ≥12 examined lymph nodes; ≥7 for T3N0M0 cases.
• An examined lymph node to regional node positive ratio of ≥9 leads to optimal survival in these patients.

Surgeons should prioritize achieving these lymph node thresholds to enhance patient prognoses.

Three-dimensional imaging technology may enhance surgical selection for neoadjuvant-treated pancreatic cancer patients.

• The 3D-PANC study compares 3D-MSP imaging accuracy to conventional CT in assessing vascular involvement.
• CT has significantly low accuracy in predicting which patients benefit from surgical resection.

This could lead to improved patient outcomes by better identifying surgical candidates.

• The study will use surgical outcomes and histopathological results as the gold standard for accuracy evaluation.

Triple therapy regimens significantly improve surgical candidacy for patients with unresectable hepatocellular carcinoma.

• Conversion to surgery rates (CSR) rise from 6% with conventional therapy to 41% with a combination of drug-eluting beads TACE, HAIC, TKI, and immune checkpoint inhibitor.
• Dual therapies yield lower CSRs (up to 15%) compared to triple therapies, emphasizing the need for combined treatment approaches.

Choosing more aggressive combination therapies can enhance surgical opportunities and outcomes for patients with unresectable disease.

• HAIC-based strategies consistently outperform conventional TACE methods.